The Diagnostic Methods commission of the International League against Epilepsy (ILAE) released a first international consensus classification of Focal Cortical Dysplasia (FCD) in 2011. Since that time, this FCD classification has been widely used in clinical diagnosis and research (more than 740 papers cited in Pubmed between 1/1/2012 and 7/1/2017). Herein, we review the new data that will inform and revise the FCD classification. Many recent papers described moleculargenetic characteristics in FCD type II including multiple mutations in the mTOR pathway. In addition, the electro-clinico-imaging phenotype and surgical outcomes of FCD type II (in particular type IIb) were further defined and validated. These results pave the way for the design of an integrated clinico-pathological and genetic classification system, as recently recommended by the WHO for the classification of malignant brain tumours.
The Diagnostic Methods commission of the International League against Epilepsy (ILAE) released a first international consensus classification of Focal Cortical Dysplasia (FCD) in 2011. Since that time, this FCD classification has been widely used in clinical diagnosis and research (more than 740 papers cited in Pubmed between 1/1/2012 and 7/1/2017). Herein, we review the new data that will inform and revise the FCD classification. Many recent papers described moleculargenetic characteristics in FCD type II including multiple mutations in the mTOR pathway. In addition, the electro-clinico-imaging phenotype and surgical outcomes of FCD type II (in particular type IIb) were further defined and validated. These results pave the way for the design of an integrated clinico-pathological and genetic classification system, as recently recommended by the WHO for the classification of malignant brain tumours.
On the other hand, little new information was acquired on FCD types I and III. Focal cortical dysplasia type I subtypes are still lacking a comprehensive description of clinical phenotypes, reproducible imaging characteristics, and specific molecular/genetic biomarkers. Associated FCD III subtypes also became rare in published literature. Despite temporal lobe epilepsy being the most common focal epilepsy in adults, we have not identified neurophysiological, imaging, histopathological and/or genetic biomarkers to reliably classify FCD III with or without hippocampal sclerosis. In respect of pathogene
Introduction
The term 'focal cortical dysplasia' was first used to describe a specific malformation of the brain that consisted of disorganized cortex with irregular dysmorphic neurons and enlarged ballooned cells [1] . Dysmorphic neurons were first described by Crome [2] and later by Taylor [1] , who identified the dysmorphic or giant neurons in temporal, frontal, parietal or occipital cortex resected from 10 patients with pharmaco-resistant epilepsy (half of them had balloon cells). Since then, focal cortical dysplasias (FCDs) have been recognized as a cause of medically intractable epilepsy [3] [4] [5] [6] . More recent outcome data showed clear differentiation in the post-resective seizure outcome between patients with type II and those with type I FCDs: where surgery on type II FCDs has been uniformly associated with better seizure outcomes as compared to type I FCDs [7] [8] [9] .
In order to create a pathology-based subdivision of FCDs with distinct clinical, electrical, imaging, outcomes, and molecular/genetic characteristics and with the overarching goals of enhanced lesional detection, better understanding of mechanisms (epilepsy and pathology), targeted medical and surgical management protocols, and well-defined outcome, the Diagnostic Methods commission of the International League against Epilepsy (ILAE) released its first international consensus classification of Focal Cortical Dysplasia (FCD) in 2011 [10] . The revised classification updated the pathological criteria of type I, and introduced a new subtype (type III) that creates mixed-pathological entities. Good inter-and intra-observer agreement for histopathological evaluation of the ILAE classification was shown by 32 neuropathologists using a collaborative virtual microscopy platform [11] .
A large body of knowledge was generated from published research since the introduction of the classification with more than 740 papers, reviews and chapters published (PubMed: 1/1/2012-7/1/2017, key words focal cortical dysplasia, epilepsy). A survey of the published data highlights the opportunities generated by the previous classification (Figure 1 ).
Embryonic and foetal pathogenesis of the FCDs
Focal cortical dysplasia might be considered in the context of human developmental neuroanatomy and pathogenetic mechanisms. The following reassessment of each of the FCDs in the current ILAE classification addresses neuroembryological and developmental data to attempt to explain pathological changes at both tissue and cellular levels, with the idea of incorporating these data into a revision of the classification scheme.
Focal cortical dysplasia type I
The descriptive lesions in focal cortical dysplasia type I (FCD I) are dyslamination and disrupted organization of tissue architecture, but with morphologically normal neurons and glial cells. Because cellular density in the cortex is little altered with disorganization, the magnetic resonance imaging (MRI) can show no visible changes and is considered as 'non-lesional'. A normal MRI does not rule out the presence of microscopic pathology, as it might just be an intrinsic limitation of the technique [12] [13] [14] . In many patients (for example those with genetic epilepsies) with normal MRI, no structural neuropathological abnormality exists [14] . The present generation of MRI does not disclose microscopic structure beneath the resolution of the naked eye and alterations in FCD I are a rearrangement of tissue architecture with normal neurons and without sufficient alterations in overall cellularity or density of the grey matter to affect the imaging signal, hence no MRI lesions are detected. However, the MRI often exhibits blurring of the grey-white matter junction, this could be possibly due to neuronal dispersion into the U-fibre layer in such 'non-lesional' cases. Therefore, the term 'non-lesional' should not be used unless qualified as referring only to visualization by MRI.
FCD Ia
Subtype Ia consists of a micro-columnar, rather than a horizontal laminar, cortical architecture. It is recognized in independent studies by many authors and is the best documented and universally accepted form of FCD I by experienced neuropathologists world-wide. In consideration of the histological reorganization of the cortical plate at or slightly after mid-gestation, at about 22 weeks in the human foetus, FCD Ia is highly reminiscent of the foetal pattern in the first half of gestation, which is distinctly micro-columnar [15] . The cortical plate is densely cellular because the large round nuclei of the post-migratory neuroblasts are surrounded by only a thin rim of cytoplasm and the intercellular neuropil is sparse because neurites and glial cells are few. Nevertheless, a radial micro-columnar architecture of the cortical plate without horizontal lamination is evident in ordinary histological stains such as haematoxylin-eosin; the late neuronal marker neuronal nuclear antigen (NeuN) that so clearly denotes this architecture postnatally, is not yet expressed in the immature neurons of the cortical plate before mid-gestation [16, 17] . The radial micro-columnar architecture in the normal foetal neocortex in the first half of gestation, before gyri and sulci form, is essentially the same in all regions. Radial micro-columns in the early human foetal cerebral cortex were first described by Santiago Ram on y Cajal from silver Golgi impregnations [18, 19] .
A quantitative study of regional differences in this context in FCD Ia is a current investigation in progress. Our initial qualitative results do not demonstrate regional differences between FCD Ia in motor and sensory cortices in children, even in regions such as occipital striate cortex that is so distinctive in layer 4 of the adult brain (Sarnat, H.B., unpub. data).
At about 22-weeks' gestation, the histological differentiation of distinctive neuronal types and sizes begins to appear and horizontal or tangential lamination gradually becomes superimposed on the radial micro-columnar pattern until it predominates in mature cerebral cortex. Persistent micro-columns are still seen in normal mature brains of children and adults, at sites of bending of a gyrus such as the gyral crown and especially the base or bottom of a sulcus, but are much less frequent and evident in the straight sides of gyri bordering a sulcus [15] . The intrinsic synaptic circuitry of the cortex also continues to be columnar with connections between columns, recognized as 'barrels' within visual and somatosensory cortex in particular, and transcranial magnetic stimulation (TMS) excites the cerebral cortex in selective radial orientation of electrical fields [20] . How many histological micro-columns in bending gyri is too many is a key point in the diagnosis of FCD Ia, but to date there is no consensus on this crucial quantitative point; radial micro-columns in the lateral wall of the same gyrus strongly favours FCD Ia over normal variants.
One perspective of FCD Ia, therefore, is that it is a focal 'maturational arrest' in cortical reorganization at mid-gestation, so that what begins as the normal pattern becomes pathological because of age and timing [15] . Synaptophysin immunoreactivity in FCD Ia often discloses radial synaptic layers alternating between neuronal micro-columns [15] , a synaptic pattern not seen in normal developing foetal cortex [21] . This pattern in FCD Ia may be limited to a single gyrus, but more frequently involves a field of several or many gyri. In some genetic and metabolic diseases (e.g. DiGeorge syndrome with chromosomal 22q21.2 deletion; methylmalonic acidaemia) a radial micro-columnar pattern is seen in a generalized distribution throughout all lobes of the cortex in both hemispheres, rather than confined to a focal zone, interpreted as a generalized delay or arrest in cortical maturation [15] . The incidence of epilepsy in early infancy in these generalized genetic and metabolic disorders is many times higher than agematched controls; seizure types vary from severe infantile epilepsies such as infantile spasms, to myoclonic epilepsy, to focal and generalized seizures [22] [23] [24] .
Another pattern seen in parts of the same gyrus in FCD Ia is a total disarray of the tissue architecture that corresponds neither to radial nor to horizontal lamination. Short microcolumns may be seen, but they are oriented randomly. Neurons are disoriented with basal dendrites facing in any direction and a few scattered large pyramidal neurons displaced into the superficial cortical layers. This type of haphazard architecture may result from loss or dysfunction of an intercellular matrix dis-adhesion molecule that serves to detach migratory neuroblasts from their radial glial guide fibres upon reaching the cortical plate. Detachment is essential to enable the line of neuroblasts behind them on the same radial glial fibre to bypass and reach the surface of the cortical plate. This process creates or preserves the normal inside-out cortical architecture; the earliest migratory cells are displaced into deeper parts of the cortical plate by more recent arrivals.
If all neuroblasts remain attached to the radial glial fibres, this normal process cannot proceed and disorganization results [25] . This pattern is not presently included in the ILAE classification, but because it is always associated with FCD Ia, it is best regarded as part of FCD Ia and not as a separate type.
FCD Ib
This pattern is described in the ILAE classification as defective horizontal lamination with lamina-specific neuronal paucity, but this pattern is much more controversial and less well accepted than FCD Ia. There are many acquired lesions that may cause neurons in selective laminae of the cortex to be more affected than others. An example is perinatal hypoxic/ischaemic injury or prolonged prenatal ischaemia; if extreme this type of injury may progress to frank laminar necrosis of the cortex, exemplified in congenital cytomegalovirus (CMV) infections in which endothelial cells of cerebral capillaries and arterioles are severely affected by viral burden. It would be difficult to classify it as type IIId because the laminar necrosis is not a single focal lesion but multifocal or generalised. If the FCD Ia pattern is in a demonstrated neuropathologically in a patient with a known acquired defect, it thus might be better classified as FCD III at the present time using the 2011 ILAE scheme.
At times, an appearance of neuronal loss within a particular lamina by NeuN is not a true loss of neurons as shown by histological stains and other immunocytochemical reactivities in adjacent sections, but rather is loss of NeuN expression from these neurons, which may not even appear histologically altered. GABAergic interneurons that are reactive with antibodies to calcium-binding antigens, such as calretinin and parvalbumin, and that arrive in the cortex by tangential migration from the ganglionic eminence rather than from radial migration, may or may not be preserved within laminae showing NeuN loss of reactivity [26] . On the other hand, lamina-specific markers of neurons by immunocytochemistry and mRNA are described [27] [28] [29] . Perhaps metabolic defects of these cellular products may indeed produce a FCD Ib as a developmental defect. The possibility that FCD Ib is a true subtype of FCD I must remain open to further confirmation and acceptance, but at the present time the evidence is insufficient.
FCD Ic
This pattern is described as a combined FCD Ia and FCD Ib. It is even less well established and accepted than FCD Ib, and is a compromise. Even if FCD Ib really exists, there are some persistent radial micro-columns in all FCDs, so that this diagnosis is frequently made by some neuropathologists but rarely diagnosed by others.
Focal geographical cortical patterns of neuronal loss
Not included in the ILAE 2011 classification are unique patterns of geographic regions with irregular shapes that affect the full thickness of the cortex or only some laminae [28, 29] . A frequent factor that can produce this pattern is artefactual, due to rough tissue handling whether of surgical specimens or at autopsy. Severe crush injuries to tissue either intraoperatively or after removal are usually evident from histological examination, but more subtle compression may cause loss of NeuN and other immunoreactivities. Gliosis would not be present. The use of recording electrodes at the brain surface and especially depth electrodes similarly traumatize brain tissue. So, the first factor to consider in viewing a section with a geographical pattern of impaired immunoreactivity or disruption of architecture is that it does not represent a true pathophysiological condition. If convincing confirmation of this geographical cortical pattern is found in other laboratories that is not attributed to artefact, this pattern might be reconsidered in future as a FCD distinct subtype, but the data are too sparse to include it in a revised scheme at this time.
Focal cortical dysplasia type II
The pathogenesis of focal cortical dysplasia type II (FCD II) is very different from that of FCD I, though some features such as focal radial micro-columnar architecture may be inconstantly seen as a secondary feature. The principal histopathological difference from FCD I is the presence of dysplastic, megalocytic neurons mixed with normal neurons (Figure 2 ). Though glia are not relevant to the definition of FCD II, glial cells also are dysplastic and often enlarged in all mTOR activation somatic mutations, including TSC, FCD II and HME [30] . Somatic mutations affecting undifferentiated neuroepithelial cells are not restricted to lineages as the clones of these cells differentiate [30] . FCD IIb is further distinguished from FCD IIa by the additional presence of balloon cells. These cells are of mixed lineage, expressing both neuronal and glial protein transcription products in hemimegalencephaly (HME) [31] and also in FCD IIb and TSC.
Neuroblasts of the sub-ventricular zone migrate toward cortical lesions as a foetal form of cortical repair by replacing neurons lost due to lesions such as a haemorrhage or microinfarct [32] . Whether they do so in response to a cortical hamartoma of FCD II or a cortical tuber in TSC is uncertain.
In disorders of cortical development associated with activation of the mTOR signalling pathway, an abnormal, mildly phosphorylated form of tau protein also is expressed, similar to tauopathies in neurodegenerative diseases in late adult life. This phenomenon was initially demonstrated in HME [33] but also is seen in FCD II, TSC and ganglioglioma, collectively called 'infantile tauopathies' [34] . In addition, tauopathy also occurs in the pachygyric cerebral cortex of Fukuyama congenital muscular dystrophy [30] . Tau is a microtubule-associated protein. The protein gene product Fukutin is important for the glycolysation of a-dystroglycan and may play a role in the maintenance of microtubules [30] . The tauopathy of FCD II and HME requires further confirmation by other laboratories before consideration as a criterion in classification.
FCD II and HME
Same dysplasia with different timing.
Microscopically, sections of cortex in FCD IIb and HME are generally indistinguishable, both showing similar findings of dysplastic megalocytic neurons, balloon cells, dyslaminated cortical architecture and abnormal glial cells, mixed with neurons and glia that appear histologically normal [33, [35] [36] [37] [38] . Both disorders involve activation of the mTOR pathway and both exhibit phosphorylated tau expression. Clinically, both disorders are highly epileptogenic and expressed in infancy or early childhood. The principal difference between FCD IIb and HME is the extent of the lesion. The lesion size can be explained in post-zygotic somatic mosaicism by the timing of when in the 33 mitotic cycles of the periventricular neuroepithelium [39] that the expression begins: if it starts late in the mitotic cycles, a small lesion restricted to one gyrus may occur; if it is initiated in a somewhat earlier cycle, larger lesion involving several adjacent gyri occurs; if ever earlier, the extent may involve an entire lobe of the brain as partial HME and a yet earlier onset causes the entire cerebral hemisphere to be dysplastic and overgrown as classical HME [25, 40] . Onset in the earliest mitotic cycles when the neuroepithelium of the forebrain and posterior fossa are continuous may yield 'total HME' in which the ipsilateral brainstem and cerebellum also are enlarged and dysplastic [38, 40] .
Hemimegalencephaly is a frequent cerebral lesion associated with neurocutaneous syndromes, in particular the epidermal naevus syndrome, including linear sebaceous and keratinocytic naevi, Proteus and CLOVES syndromes [41] . The cutaneous naevi in these diseases are due to neural crest involvement with the post-zygotic somatic mosaicism.
The cortical tubers of TSC also may show similar histopathological findings to those of FCD IIb and HME, but also may contain dystrophic calcifications that are infrequent in FCD of all types and in HME, hence provide a clue to diagnosis.
Focal cortical dysplasias type III: FCD I adjacent to another principal lesion
This category of Focal cortical dysplasias type III (FCD III) is valid and it should be emphasized that it corresponds to dyslamination with normal neurons (FCD I) but adjacent to another principal lesion.
Sub-type IIIa (adjacent to hippocampal sclerosis), with qualification that the FCD must be in the temporal lobe near the hippocampus, not in a more remote part of the neocortex, is problematic from the perspective of pathogenesis. FCD I and II are congenital developmental lesions arising in embryonic or foetal life, but hippocampal sclerosis is an acquired lesion, usually after many years. One cannot, therefore, attribute FCD IIIa to a maturational arrest as with FCD I or to somatic mosaicism as with FCD II. Furthermore, there is a greater variability in the normal range of neuroanatomy in the temporal lobe than in other parts of the cortex. The subiculum often has a nodular more than laminar character, and layer 4 of neocortex often is poorly developed or nearly absent in parts of the parahippocampal gyrus in otherwise normal brains. The pathogenesis of FCD IIIa requires better documentation.
FCD IIIb (adjacent to a tumour) is also problematic if adjacent to a postnatally acquired tumour, though less controversial if adjacent to a presumed congenital developmental tumour of the cortex such as ganglioglioma (GG) or dysembryoplastic neuroepithelial tumour (DNET). There is no evidence to support that a congenital FCD was primary and later underwent neoplastic transformation. An exception might be the subependymal giant cell astrocytomas (SEGA) in TSC that may arise from subependymal glial nodules, but cortical tubers are not neoplastic. FCD IIIb therefore could be retained, but further specified as adjacent to a developmental tumour rather than adjacent to an astrocytoma or ependymoma.
FCD IIIc (adjacent to a vascular malformation) might be retained because most vascular malformations are developmental and perhaps chronic low-grade ischaemia in adjacent cortex leads to maturational arrest with micro-columnar histological architecture.
Sub-type IIId is presently a 'wastebasket' category of various unrelated lesions that are not IIIa, b, c, but one could justify restricting IIId to ischemic lesions during development: laminar necrosis; micro-infarcts; large infarcts of major cerebral artery occlusion (porencephaly); and haemorrhages. There may be some overlap with IIIc, as vascular malformations also may cause ischemia of surrounding tissue, but primary vascular malformations are easily distinguished neuropathologically. The reason for radial micro-columnar cortical architecture adjacent to a foetal infarct or porencephalic cyst that occurred at mid-gestation is maturational arrest of an ischemic zone that was not quite severe enough to be included in the frank infarct. Foetal ischemia after mid-gestation or perinatal ischemia may produce a laminar lesion that in later life is epileptogenic [42] and this new sub-type IIId of ischemic lesions might be a better classification than the earlier FCD Ib. FCD adjacent to postnatally acquired infarcts presents the same problem of pathogenesis with non-developmental lesions already mentioned. If IIId is specified as ischaemic lesions dating from foetal life, a new sub-type IIIe could be available for any remaining lesions, such as inflammatory and traumatic encephalopathies, though these are not usually developmental conditions so that pathogenesis is difficult to explain, and documentation of FCD associated with such lesions is very incomplete and perhaps does not even exist.
Supplemental neuropathological features
Several additional histopathological features are now reported, for which the data remain incomplete for inclusion in the ILAE Classification at this time, but they might be noted as secondary or supplemental neuropathological features in the future. One example is the neuronal dispersion and synaptic plexi within the U-fibre layer beneath focal cortical dysplasias I and II that can participate in epileptic networks (Sarnat, H.B., unpubl. obs.). Another example is the upregulation of the heat shock protein a-B-crystallin in glial cells and sometimes neurones at the site of an electrographic epileptic cortical focus [43] . Even the rare histologically 'non-lesional' epileptic foci can be restated as 'lesional' if this immunoreactivity is applied, because it is positive in all cases that we have studied (Sarnat, H.B., unpubl. obs.).
Genetics of FCDs (see also review article of Marsan and Baulac in this issue)
Almost 18% of the aforementioned 740 publications of FCD listed in PubMed reported on genetics. At the time of preparation of this manuscript, at least nine studies reported pathogenic variants in mTOR pathway associated genes in 32 patients (25% of tested patients) with histopathologically confirmed FCD II [44] [45] [46] [47] [48] [49] [50] [51] [52] . The majority of variants have been reported as brain somatic mutations and predominantly affected the mTOR or DEPDC5 genes. These data call for extended molecular-genetic investigations integrating ultra-deep genome-wide DNA and single-cell RNA sequencing as well as methylome and proteomic analysis to identify the pathogenic cause in all FCD patients.
A recent study showed that focal cortical expression of mutant mTOR by in utero electroporation in mice led to a disruption in neuronal migration, the appearance of cytomegalic neurons and spontaneous seizures. Inhibition of mTOR with rapamycin suppressed cytomegalic neurons and epileptic seizures. This study provided evidence for a role of somatic mTOR pathway activation in the pathophysiology of type II FCD and identified mTOR as a possible treatment target for epilepsy due to FCD. [46] . Negishi et al. recently reported on a combination of genetic and biochemical methods for the diagnosis of mTOR pathway-associated megalencephaly using lymphoblastoid cell lines from 12 patients. Increased expression of phospho-S6 protein was demonstrated in mutation-positive and mutation-negative patients in whom western blotting was performed. This approach could be useful to identify patients who are suitable for the diagnosis of mTORopathies and the design of future clinical trials using an mTOR inhibitor [53] .
The published genetic data further link FCD II with two developmental pathologies that are not included in the FCD classification, HME and tuberous sclerosis complex, defining the histopathological lesion spectrum with distinct dysmorphic neurons as mTORopathy [51, 54, 55] .
The development of truly representative animal models has been lagging behind as only 5% (n = 42) of the studies reported on animal models of some FCD subtypes (no animal models of FCD IIb). But animal studies, and studies on tissue resected from human epilepsies of patients with various types of FCDs identified possible roles for the upregulation of various excitatory amino-acid receptors (such as glutamate receptors) and the down regulation of inhibitory receptors (such as GABA receptors) in the expression of epileptogenicity. In addition, animal models identified the possible roles of 'second hit' mechanisms in the development of the epilepsy phenotype in some forms of non FCD IIb animal pathologies [56] [57] [58] .
Electro-imaging-outcomes of FCDs
Type II FCDs became much better characterized clinical entities in patients with epilepsy with well-defined EEG, MRI, surgical management protocols, and outcome characteristics. EEG and MRI signatures of FCD IIa and IIb have been further validated. The specificity of some interictal patterns such as focal continuous rhythmic discharges, repetitive spiking and paroxysmal fast activities have been suggested as possible predictors of the ictal onset zone in type II FCDs and of favourable postresection seizure outcome [59] . A recent study showed the intrinsic epileptogenicity may not overlap with the MRI-observed abnormality and balloon cell density [60, 61] .
Magnetic resonance imaging (MRI) techniques have provided a non-invasive window for the characterization of some forms of FCDs. Non-specific MRI changes were described for FCD Type I lesions: These include white-matter-volume-reduction and subtle increased signals on FLAIR and T2 images. But the MRI is normal in the majority of patients with type 1 FCD [62, 63] . FCD Type III lesions share the typical features of the associated lesions [64] . Although the majority of patients with type II FCD show focal MRI abnormalities, almost one-third of them remain MRI negative [65] . MRI abnormalities in FCD Type II include cortical thickness changes, signal increase (mainly FLAIR), and grey-white matter blurring. Recent reports confirmed the diagnostic signature of the 'transmantle' sign in FCD IIb. In addition, recent studies reported on the MRI post-processing role in the identification of type II FCDs [62, 63, [66] [67] [68] [69] [70] [71] .
Almost half of the studies (since 2012) reported on 'surgery' involving patients with FCDs. These reports highlighted the difficulties in approaching FCD type I: Even the use of the most invasive evaluation techniques fails to localize the epileptogenic zone (EZ) and subsequently results in no resections or failed surgical resections. These failures could also be due to more widespread epileptic pathology. On the other hand, the pre-surgical evaluation of patients with suspected FCD type II have become more streamlined, and in some instances (in particular in type IIb or bottom of sulcus FCDs), EZ localization and mapping with excellent results have been achieved without extra-operative invasive evaluations.
Surgical outcome studies (28% of the reports, n = 221) clearly established the successes and the challenges facing the current FCD classification. Excellent seizure outcomes were associated with surgical resections involving type II FCDs. But non-favourable outcomes have been reported after resections of type I FCDs with the outcomes of type III FCDs depending on the pathology associated with FCD.
Challenges identified in the 2011 Classification
Although we may all agree that distinct FCD subtypes exist and at least some of them can be ascribed to a characteristic clinico-pathological phenotype, the current ILAE classification harbours many challenges in the histopathological diagnosis of FCD subtypes as well as the ambiguous hypotheses about specific pathogenesis of these focal malformations. Deciphering the molecular-genetic type will not only help to comprehensively classify a given malformation into clinically meaningful categories but also lead to the development of targeted treatment options. A best example for this strategy is FCD Type II with circumscribed localization in the bottom-of-sulcus, mostly in the frontal lobe [72] . Activating mutations in the mTOR signalling pathway are another hallmark of this disease and can be pharmacologically targeted by derivatives of rapamycin [73] .
Ongoing concern remain about the histopathological benchmarks of specific FCD I subtypes and their clinical significance. Amongst the three subtypes of FCD I suggested by the 2011 classification scheme, only those with extensive radial organization of neuronal microcolumns can resist a careful and critical review (FCD Ia) [63, 74, 75] . Its clinical phenotype is almost always associated with epilepsy onset in very young children, involvement of large brain regions and cognitive impairment. On the other hand, distinct examples of FCD Ib and Ic are limited in the current literature with no clear clinical/imaging phenotype(s). A major reason might be the ambiguous histopathological criteria. Indeed, panel C of figure 2 from the original ILAE publication in 2011 showed an example of FCD Ib, which will need revision and reclassification as FCD IIId. A recent report showed evidence that loss of layer 4 neurons results from early (perinatal) hypoxic-ischemic injury in the occipital lobe [42] . Histopathology of FCD Ic was never described before the ILAE classification in 2011 as FCD. It quickly developed as a 'wastebasket' of cases clinically suspected as FCD with no abnormal MRI findings with no systematic histopathology review [76] . Importantly, FCD I subtypes lack any comprehensive publication that characterizes their molecular genotype.
As in previous classification schemes [77, 78] , FCD Type II remains best recognized in the recent literature. There is increasing evidence for 10-20% of lesions being associated with a constitutively activated mTOR signalling pathway [46, 79] . Unsolved questions remain about the lack of molecular-genetic findings in those 80% of lesions not carrying a mutation, despite ultradeep sequencing and all efforts to increase the availability of pathogenic tissue genetic analysis. A second point of continuous discussion is whether FCD IIa and IIb subtypes truly represent distinct entities as their distinction can yet be defined only by presence or absence of balloon cells. On the other hand, one may argue that similar clinical presentation, genetic findings and preferred localization would be compatible with both lesions representing as spectrum of the same disorder.
Another challenging issue and a reason for contradictory discussions were FCD associated with other principal lesions, such as hippocampal sclerosis (FCD Type IIIa) [80] , brain tumours (FCD Type IIIb), vascular malformations (FCD Type IIIc) or other lesions acquired during early life (perinatal stroke, inflammation etc.; FCD IIId). Historically, this FCD category must be considered most prevalent in scientific literature as they were described often as FCD Type I by the Palmini classification or architectural dysplasia associated with MTLE or tumours [77, 78, 81] . This latter group should now classify as FCD IIIa, but research interest did not increase significantly after the ILAE consensus classification. In contrast, imaging features suspected as FCD in temporal lobe epilepsy, that is, grey-white matter blurring and temporo-polar atrophy, were shown to represent white matter alterations [82] . The same applies to FCD IIIb associated with brain tumours. The original description of DNETs claimed FCD as a frequently encountered cortical lesion [83] . Systematic histopathological reviews using refined panels of immunohistochemical marker proteins did not support these findings [10, 80, 84, 85] . Diffuse and infiltrative behaviour of many epilepsy-associated glio-neuronal tumours can mimic such FCD and must be excluded according to the ILAE classification scheme for FCD IIIb. It has not been shown hitherto that FCD IIIb follow a specific patho-mechanism, molecular-genetic signature and/or clinical behaviour different from those tumours without FCD IIIb, e.g. does postsurgical seizure relapse depend on size of cortical resection field or is there any relationship with tumour aetiology and risk for progression [80] ?.
Less conflicting results were published for FCD IIIc and IIId phenotypes [86, 87] . Sturge-Weber syndrome (SWS) almost always showed histopathological signs of complex architectural dysplasia consisting of radial and vertical disorganization of the neocortex [87] .This FCD subtype is less frequently detected in cavernomas (CAV) and arterio-venous malformations (AVM). However, hypertrophic neurons can be often encountered in affected cortex, which require careful differentiation from dysmorphic neurons in FCD IIa [88] . The association of SWS, CAV or AVM with FCD II should be considered as double pathology underlying two independent patho-mechanisms, and thus being very rare even in large series collecting epilepsy surgery specimen (Bl€ umcke, unpubl. obs.). Perinatal hypoxaemia, bleeding and inflammatory disorders such as early onset Rasmussen's encephalitis are most common principal lesions associated with FCD IIId [87] . Prominent admixture of radial and vertical architectural disorganization adjacent to glial scars were common features of this FCD subtype [86] . These data likely confirm the existence of post-migratory plasticity as cause of associated FCD phenotypes, as anticipated by the ILAE Task Force proposing the first international consensus classification scheme of FCD [10, 26] . Our suggestions for a possible update of the ILAE FCD classification are summarized in Table 1 .
Conclusions
The consensus ILAE classification of FCD generated significant amount of interest as evidenced by the large number of publications that were published over the last 5 years. Type II FCDs have been further characterized at the imaging, clinical, and genetic levels with favourable and consistently published outcome results.
On the other hand, many challenges remain in regard to the histopathological characterization of type I FCDs with some exception (radial microcolumns). These challenges highlight the need for serious consideration of the approach to these FCD subtypes, their pathophysiological/genetic mechanisms and their electro-clinicoimaging characteristics. FCDs with other principal lesions were the subjects of multiple contradictory discussions, in particular those associated with hippocampal sclerosis (Type IIIa), and brain tumours (Type IIIb). Bottom of sulcus FCD is a more recently described histopathological/anatomical/electro-clinico-imaging entity that was characterized over the last 5 years with clear histology (balloon cells), localization (bottom of sulcus), electrical (in situ epileptogenicity), imaging (signal FLAIR increase) and outcome data (excellent seizure free outcome), but is FCD IIb and not an additional distinct type. In sum, further research is needed to characterize various subtypes of FCDs with the aim of achieving more clear definition of the various pathological entities in context of molecular/genetic mechanisms and clinical practice. The present 2011 ILAE categories of FCD Ib, Ic, and all subtypes of FCD III are the most in question and perhaps could be eliminated in a revised, simplified classification scheme.
